Abstract | PURPOSE: The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, dosing, and administration of abatacept are discussed. SUMMARY: CONCLUSION:
Abatacept, a newly approved agent for the treatment of rheumatoid arthritis, has shown promising results in patients who have had an inadequate response to other treatment modalities. Abatacept therapy should be reserved for patients who have failed other time-tested treatment modalities, including TNF-alpha antagonists. Results from ongoing postmarketing studies will help determine abatacept's place in therapy.
|
Authors | Burgunda V Sweet |
Journal | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
(Am J Health Syst Pharm)
Vol. 63
Issue 21
Pg. 2065-77
(Nov 01 2006)
ISSN: 1079-2082 [Print] England |
PMID | 17057043
(Publication Type: Journal Article)
|
Chemical References |
- Immunoconjugates
- Abatacept
|
Topics |
- Abatacept
- Arthritis, Rheumatoid
(drug therapy)
- Clinical Trials, Phase II as Topic
- Humans
- Immunoconjugates
(administration & dosage, adverse effects, economics, pharmacokinetics, pharmacology)
- Treatment Outcome
|